Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.

Jean-Baptiste Trouiller Georgios F NikolaidisBérengère MacabeoNicolas MeyerLaetitia GerlierMax SchlueterPhilippe Laramee

Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2023)

EncoBini is associated with reduced costs and increased QALYs, dominating other targeted double combination therapies (DabraTrame, VemuCobi) for patients with BRAF V600-mutant MM in France. EncoBini is a highly cost-effective intervention in MM.

Keyphrases

wild type
randomized controlled trial
squamous cell carcinoma

small cell lung cancer
metastatic colorectal cancer
locally advanced

cancer therapy
liver metastases

skin cancer
rectal cancer